organization · Reporting owner

Column Group Opportunity III, LP

Disclosed activity across 4 companies

Tapewire entity: 64489
SEC CIK: 0001931825

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Eikon Therapeutics, Inc.EIKN · Entity 5380	10% owner	September 03, 2026	September 08, 2026
NGM BIOPHARMACEUTICALS INCNGM · Entity 11997	10% owner	April 05, 2024	April 08, 2024
Surrozen, Inc./DESRZN · Entity 6092	10% owner	January 15, 2026	January 20, 2026
Tenaya Therapeutics, Inc.TNYA · Entity 6506	10% owner	February 24, 2026	February 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Eikon Therapeutics, Inc.

Report date September 03, 2026 · Filed September 08, 2026

Jointly reported with Column Group IV GP, LP, Column Group IV-A, LP, Column Group IV, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	89,200	Reported balance After 2026-09-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-03 · Purchase · Acquired 89,200 · Balance 89,200 F1: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: The securities are directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group IV, LP	4,312,139	Reported balance Holding disclosure · report date 2026-09-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,312,139 F3: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to securities directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group IV-A, LP	148,840	Reported balance Holding disclosure · report date 2026-09-03 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 148,840 F4: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to securities directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group Opportunity III, LP	1,319,164	Reported balance Holding disclosure · report date 2026-09-03 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,319,164 F5: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2: The securities are directly held by Peter Svennilson.

F3: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to securities directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

F4: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to securities directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

F5: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III GP, LP, Column Group IV, LP, Column Group IV-A, LP, Column Group IV GP, LP, TCG IV GP, LLC, Column Group Opportunity III GP, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,000	Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Surrozen, Inc./DE

Report date January 15, 2026 · Filed January 20, 2026

Jointly reported with COLUMN GROUP III GP, LP, COLUMN GROUP III-A, LP, COLUMN GROUP III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Svennilson Peter

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Column Group III, LP	900,292	Last balance in matching sequence After 2026-01-20 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-01-15 · Purchase · Acquired 5,590 · Balance 890,604 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 3 · 2026-01-16 · Purchase · Acquired 1,204 · Balance 891,808 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 5 · 2026-01-20 · Purchase · Acquired 8,484 · Balance 900,292 F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group III-A, LP	1,016,658	Last balance in matching sequence After 2026-01-20 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2026-01-15 · Purchase · Acquired 6,303 · Balance 1,005,732 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 4 · 2026-01-16 · Purchase · Acquired 1,358 · Balance 1,007,090 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Row 6 · 2026-01-20 · Purchase · Acquired 9,568 · Balance 1,016,658 F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectBy The Column Group Opportunity III, LP	344,827	Reported balance Holding disclosure · report date 2026-01-15 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 344,827 F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F2: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F3: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Tenaya Therapeutics, Inc.

Report date February 24, 2026 · Filed February 26, 2026

Jointly reported with COLUMN GROUP III GP, LP, COLUMN GROUP III, LP, COLUMN GROUP III-A, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,649,281	Reported balance After 2026-02-24 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-02-24 · Sale · Disposed 309,228 · Balance 1,649,281 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,862,545	Reported balance After 2026-02-24 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-02-24 · Sale · Disposed 349,212 · Balance 1,862,545 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-02-25 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-02-25 · Sale · Disposed 1,649,281 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-02-25 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2026-02-25 · Sale · Disposed 1,862,545 · Balance 0 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	49,313,559	Reported balance Holding disclosure · report date 2026-02-24 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 49,313,559 F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F3: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F5: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 03, 2026 Filed Sep 8, 2026 20:33 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	PurchaseCommon Stock	89,200	$11.56	$1,031,044.96	Disclosure SEC source: 0001193125-26-385268 · ownership.xml · nonDerivative · entry 1 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 89,200 F1 · price: The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by Peter Svennilson. Read SEC document
February 25, 2026 Filed Feb 26, 2026 16:23 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	1,862,545	$0.56	$1,047,495.31	Disclosure SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 25, 2026 Filed Feb 26, 2026 16:23 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	1,649,281	$0.56	$927,555.63	Disclosure SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 24, 2026 Filed Feb 26, 2026 16:23 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	349,212	$0.62	$214,870.14	Disclosure SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,862,545 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 24, 2026 Filed Feb 26, 2026 16:23 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	309,228	$0.62	$190,267.99	Disclosure SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,649,281 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 23, 2026 Filed Feb 24, 2026 16:13 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	162,291	$0.60	$96,920.19	Disclosure SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,211,757 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 23, 2026 Filed Feb 24, 2026 16:13 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	143,709	$0.60	$85,823.01	Disclosure SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,958,509 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 20, 2026 Filed Feb 24, 2026 16:13 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	277,769	$0.61	$170,800.16	Disclosure SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,374,048 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 20, 2026 Filed Feb 24, 2026 16:13 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	245,965	$0.61	$151,243.88	Disclosure SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,102,218 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 11, 2026 Filed Feb 12, 2026 17:19 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	2,151,458	$0.68	$1,464,712.61	Disclosure SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,651,817 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 11, 2026 Filed Feb 12, 2026 17:19 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	1,905,115	$0.68	$1,297,002.29	Disclosure SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,348,183 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 10, 2026 Filed Feb 12, 2026 17:19 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	182,295	$0.82	$148,770.95	Disclosure SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,803,275 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 10, 2026 Filed Feb 12, 2026 17:19 UTC	Tenaya Therapeutics, Inc. TNYA · Entity 6506	SaleCommon Stock	161,422	$0.82	$131,736.49	Disclosure SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,253,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries D Preferred Stock · Derivative	5,133,076	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 17 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 0 Underlying: Common Stock · 688,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries C-1 Preferred Stock · Derivative	28,229	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 16 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 3,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries C-1 Preferred Stock · Derivative	827,278	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 15 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 110,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries A-1 Preferred Stock · Derivative	357,216	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 14 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 47,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries A-1 Preferred Stock · Derivative	10,467,526	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 13 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 1,403,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries A Preferred Stock · Derivative	330,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 12 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 0 Underlying: Common Stock · 44,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionSeries A Preferred Stock · Derivative	9,670,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · derivative · entry 11 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 0 Underlying: Common Stock · 1,296,629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	PurchaseCommon Stock	630,881	$18.00	$11,355,858.00	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 10 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 1,319,164 F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	PurchaseCommon Stock	49,556	$18.00	$892,008.00	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 9 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 148,840 F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	PurchaseCommon Stock	1,437,323	$18.00	$25,871,814.00	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 8 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 4,312,139 F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	688,283	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 7 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity III, LP Disclosed balance after: 688,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F4 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	3,785	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 6 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 99,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	47,898	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 5 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 95,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	44,249	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 4 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV-A, LP Disclosed balance after: 47,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F3 · ownership.nature: The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	110,928	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 3 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 2,874,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	1,403,568	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 2 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 2,763,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
February 06, 2026 Filed Feb 10, 2026 02:19 UTC	Eikon Therapeutics, Inc. EIKN · Entity 5380	ConversionCommon Stock	1,296,629	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-043320 · ownership.xml · nonDerivative · entry 1 Column Group IV GP, LP · CIK 0001796356 · 10% owner Column Group IV-A, LP · CIK 0001796353 · 10% owner Column Group IV, LP · CIK 0001796354 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group IV, LP Disclosed balance after: 1,360,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F1 · price: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of the Issuer's Common Stock and has no expiration date F2 · ownership.nature: The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein. Read SEC document
January 20, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	9,568	$19.60	$187,531.84	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 6 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,016,658 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 20, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	8,484	$19.60	$166,285.55	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 5 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 900,292 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 16, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	1,358	$20.00	$27,160.00	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,007,090 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 16, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	1,204	$20.00	$24,080.00	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 891,808 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 15, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	6,303	$19.89	$125,360.37	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 1,005,732 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 15, 2026 Filed Jan 20, 2026 19:35 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	5,590	$19.89	$111,179.51	Disclosure SEC source: 0001193125-26-016991 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 890,604 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 14, 2026 Filed Jan 15, 2026 16:10 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	2,927	$19.99	$58,505.75	Disclosure SEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 999,429 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 14, 2026 Filed Jan 15, 2026 16:10 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	2,596	$19.99	$51,889.63	Disclosure SEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 885,014 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 13, 2026 Filed Jan 15, 2026 16:10 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	6,609	$19.80	$130,885.30	Disclosure SEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 996,502 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 13, 2026 Filed Jan 15, 2026 16:10 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	5,861	$19.80	$116,071.83	Disclosure SEC source: 0001193125-26-014100 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 882,418 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 06, 2026 Filed Jan 8, 2026 17:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	8,003	$19.89	$159,157.26	Disclosure SEC source: 0001193125-26-007857 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 989,893 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
January 06, 2026 Filed Jan 8, 2026 17:23 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	7,097	$19.89	$141,139.46	Disclosure SEC source: 0001193125-26-007857 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Svennilson Peter · CIK 0001606074 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 876,557 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
December 05, 2025 Filed Dec 8, 2025 17:04 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	16,381	$19.54	$320,099.48	Disclosure SEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 4 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 981,890 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
December 05, 2025 Filed Dec 8, 2025 17:04 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	14,503	$19.54	$283,401.67	Disclosure SEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 869,460 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
December 04, 2025 Filed Dec 8, 2025 17:04 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	2,791	$17.35	$48,415.48	Disclosure SEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 3 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 965,509 F2 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
December 04, 2025 Filed Dec 8, 2025 17:04 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	2,475	$17.35	$42,933.83	Disclosure SEC source: 0001193125-25-311384 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 854,957 F1 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 13, 2025 Filed Nov 17, 2025 19:15 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	167,307	$12.65	$2,116,433.55	Disclosure SEC source: 0001193125-25-284943 · ownership.xml · nonDerivative · entry 2 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 962,718 F2 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
November 13, 2025 Filed Nov 17, 2025 19:15 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseCommon Stock	148,150	$12.65	$1,874,097.50	Disclosure SEC source: 0001193125-25-284943 · ownership.xml · nonDerivative · entry 1 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III, LP Disclosed balance after: 852,482 F1 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 26, 2025 Filed Mar 28, 2025 20:57 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSecond Tranche Units (Right to Buy) · Derivative	517,241	Not disclosed Strike: $11.60	Not disclosed	Disclosure SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 21 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group Opportunity II, LP Disclosed balance after: 517,241 Underlying: Common Stock · 775,861 shares Expires not disclosed F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F15 · derivative.underlying_shares: Consists of (a) 517,241 shares of the Issuer's Common Stock and (b) 258,620 Series E Warrants to purchase shares of the Issuer's Common Stock. F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document
March 26, 2025 Filed Mar 28, 2025 20:57 UTC	Surrozen, Inc./DE SRZN · Entity 6092	PurchaseSecond Tranche Units (Right to Buy) · Derivative	548,653	Not disclosed Strike: $11.60	Not disclosed	Disclosure SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 20 COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner Column Group Opportunity III, LP · CIK 0001931825 · 10% owner Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By The Column Group III-A, LP Disclosed balance after: 548,653 Underlying: Common Stock · 822,980 shares Expires not disclosed F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice"). F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing. F14 · derivative.underlying_shares: Consists of (a) 548,653 shares of the Issuer's Common Stock and (b) 274,327 Series E Warrants to purchase shares of the Issuer's Common Stock. F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.